Last reviewed · How we verify
NCT04673760
The PROAKTIV Study
NA trial testing Specialized palliative home care in Palliative Care in 149 participants. Completed in 1 August 2023.
10 April 2022
Quick facts
| Lead sponsor | Insel Gruppe AG, University Hospital Bern |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 149 |
| Start date | 7 September 2020 |
| Primary completion | 10 April 2022 |
| Estimated completion | 1 August 2023 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Specialized palliative home care
Conditions studied
- Palliative Care — all drugs for Palliative Care →
Sponsor
Insel Gruppe AG, University Hospital Bern
Who can join
18 and older, any sex, with Palliative Care. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall objective of this study is to identify whether the systematic anticipation of highly structured specialized palliative home care into primary care influences the quality of care and care utilization. Quality of care focusses on the sense of security of patients and family caregivers, satisfaction with care of patients, family caregivers, general practitioners, home care nurses and specialized palliative care nurses, and availability and access to advanced directives. Health care utilization focus on the number of hospitalizations and the length of hospital stays.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04673760
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Palliative Care
Currently open trials in the same condition.
- NCT07505706 — Patient Journey in Palliative Care Within the NOVO Hospital Group. · active not recruiting
- NCT07469761 — MultidISciplinary Care paThway tailoRed on frAilty in Cancer Patients Referred to Outpatient paLliative Care · NA · recruiting
- NCT06588556 — Improving Needs Among Older Adults · NA · recruiting
- NCT07109050 — Virtual Reality Within Palliative Care (VR-SPC) · NA · recruiting
- NCT06771999 — Attitudes Towards Deprescribing Medications in Cancer Patients and Impact of Educational Intervention by a Clinical Phar · NA · recruiting
Other Insel Gruppe AG, University Hospital Bern trials
Trials by the same sponsor.
- NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
- NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
- NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
- NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
- NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04673760 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
- Last refreshed: 29 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04673760.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing